Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 4 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
6 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

One-time zoledronate infusion after denosumab therapy may prevent bone loss for years

23 Jun 2020

Administering a single infusion of zoledronate 6 months after denosumab therapy completion helps maintain the attained increases in bone mass density (BMD) for 3 years, as shown in a study. However, there is still a small number of patients who will require additional osteoporotic treatment.

The current analysis included 23 women (mean age, 65.7 years; mean body mass index [BMI], 29.3 kg/m2) who completed the 1-year follow-up observational extension of a previously reported 2-year multicentre prospective randomized clinical trial. All patients had received a mean of 4.8 denosumab injections over a mean 2.4 years prior to zoledronate (5 mg intravenously) administration.

The primary endpoint of change in lumbar spine bone mineral density (LS-BMD) at year 3 was not significant relative to year-2 values (mean, −1.2 percent; p=1.00) and to baseline values (mean, −1.75 percent; p=1.00).

While FN-BMD and C-terminal telopeptide of type 1 collagen (CTX) values remained unchanged, procollagen type 1 N -terminal propeptide (P1NP) values decreased during the third year of treatment. BMD values returned to the osteoporotic range in four patients.

No new clinical or morphometric vertebral fractures occurred, but one woman sustained a low-energy fracture of the right fifth metatarsal.

Researchers underscored a need for further investigation of determinants of responses with zoledronate, as well as the importance of the duration of denosumab treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 4 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
6 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.